Related Experiment Video
Updated: Nov 8, 2025
10:08
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
Published on: November 22, 2024
1.2K
Low-Risk Essential Thrombocythemia: A Comprehensive Review.
Andrew J Robinson1, Anna L Godfrey1
1Haematopathology and Oncology Diagnostics Service/Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Hemasphere
|April 21, 2021
Summary
Essential thrombocythemia (ET) management varies by risk. Low-risk ET patients often need minimal intervention, while high-risk individuals benefit from platelet count reduction via cytoreductive therapy.
Area of Science:
- Hematology
- Oncology
- Molecular Diagnostics
Background:
- Essential thrombocythemia (ET) is a myeloproliferative neoplasm marked by high platelet counts.
- Uncontrolled thrombocytosis increases risks of thrombosis and hemorrhage.
- Risk stratification guides treatment decisions for ET patients.
Purpose of the Study:
- To review the diagnostic pathway for unexplained thrombocytosis.
- To discuss risk stratification methods and their application with genomic testing.
- To outline treatment approaches for low-risk ET patients.
Main Methods:
- Review of diagnostic criteria for essential thrombocythemia.
- Analysis of molecular investigations, including JAK2, CALR, and MPL mutations.
- Evaluation of conventional and novel risk stratification tools.
- Discussion of antiplatelet therapy and cytoreductive options.
Main Results:
- Diagnostic workup includes molecular screening and bone marrow biopsy.
- Risk stratification is crucial for tailoring treatment in ET.
- Many low-risk ET patients may require minimal or no intervention.
Conclusions:
- Accurate diagnosis and risk assessment are key in managing essential thrombocythemia.
- Treatment strategies should be individualized based on patient risk.
- Further research is needed to address clinical needs in ET management.
More Related Videos
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
91
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
91
01:30Venous Thrombosis IV: Nursing Management
69
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
69
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
01:30Venous Thrombosis I: Introduction
103
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
103
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
100
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
100
01:16Therapeutic Drug Monitoring: Overview and Classification
85
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
85